Shots:

• The P-III HAWK (6/3mg) & HARRIER (6mg) study assessing Beovu [q12w/q8w with the majority on q12w following the loading phase) vs aflibercept (2mg) in 1-800 patients with wet AMD across 400 centers
• Results: first analysis ewer patients had early persistent fluid (12.5% vs 20.4%)- defined as the presence of intra-retinal fluid or subretinal fluid through @12wks. treatment- patients gain greater BVCA (6.4 vs.3.7)- CST control (80% vs 69%) respectively- presented at EURETINA
•  Beovu is the first advanced humanized scFv- approved for clinical use in 40+ countries- including in the US- EU- UK- Japan- Canada- and Australia

­ Ref: Novartis | Image: Novartis